SFE Safeguard Scientifics
Filed: 6 May 21, 4:03pm
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2021
Safeguard Scientifics, Inc.
(Exact Name of registrant as Specified in Charter)
(State or other Jurisdiction of
|(Commission File Number)||(IRS Employer ID No.)|
150 N. Radnor Chester Rd., STE F-200
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code: 610-293-0600
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock ($.10 par value)||SFE||New York Stock Exchange|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
Item 2.02. Results of Operations and Financial Condition.
On May 6, 2021 Safeguard Scientifics, Inc. (the “Company”) issued a press release (the “Press Release”) setting forth the Company’s financial information for the first quarter ended March 31, 2021.
Item 7.01. Regulation FD Disclosure.
On May 6, 2021, the Company also announced in the Press Release that its Board of Directors (the “Board”) authorized the Company, from time to time and depending on market conditions, to repurchase shares of the Company’s outstanding common stock, with up to an aggregate value of $6 million. These repurchases will be made in open market or privately negotiated transactions pursuant to a plan adopted in compliance with Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The manner, timing and amount of any purchases will be determined by the Company based upon an evaluation of market conditions, stock price and other factors. The Board’s authorization does not obligate the Company to acquire any particular amount of common stock and may be modified or suspended at any time, at the Company’s discretion.
A copy of the Press Release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits.
Cover Page Interactive Data File (formatted as Inline XBRL).
Safeguard Scientifics, Inc.
|Date: May 6, 2021||By:||/s/ G. Matthew Barnard|
|Name: G. Matthew Barnard|
|Title: General Counsel|